The Antibody Molecule: From antitoxins to therapeutic antibodies

Author:   Anthony R. Rees (, Formerly Chief Scientific Officer (CSO) Biotage AB, Uppsala, Sweden (2010-2014))
Publisher:   Oxford University Press
ISBN:  

9780199646579


Pages:   384
Publication Date:   30 October 2014
Format:   Hardback
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Our Price $125.95 Quantity:  
Add to Cart

Share |

The Antibody Molecule: From antitoxins to therapeutic antibodies


Add your own review!

Overview

Full Product Details

Author:   Anthony R. Rees (, Formerly Chief Scientific Officer (CSO) Biotage AB, Uppsala, Sweden (2010-2014))
Publisher:   Oxford University Press
Imprint:   Oxford University Press
Dimensions:   Width: 16.70cm , Height: 2.60cm , Length: 24.20cm
Weight:   0.718kg
ISBN:  

9780199646579


ISBN 10:   0199646570
Pages:   384
Publication Date:   30 October 2014
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

1: Antibody pre-history: The emergence of empirical immunology 2: Pre-molecular immunology: The dawn of mechanism 3: Structural chemistry: Locks, keys and colloids 4: The foundations of antibody-antigen recognition emerge 5: The cellular reformation 6: The molecular path unfolds 7: Uncovering the origins of antibody diversity 8: Immunoglobulin constant regions 9: Effector functions of constant regions 10: Transmission and catabolism of IgG 11: The structural context of antibody diversity 12: Monoclonal antibodies and the mechanisms of hypermutation 13: Antibody structure prediction and development of humanization strategies 14: Antibody engineering: Improving on natural immunity 15: Therapeutic antibodies: Case study 1: Prevention of respiratory syncytial virus illness 16: Therapeutic antibodies: Case study 2: Targeting breast cancer 17: Antibodies: The therapeutic future

Reviews

An enjoyable read and I would thoroughly recommend it to anyone who wants to learn about the stories that lie behind the modern textbook understanding of the antibody molecule and its therapeutic applications. * Mike Clark, Reader in Therapeutic and Molecular Immunology (Retired), University of Cambridge; British Journal of Cardiology, 22 (25), 2015 * The Antibody Molecule is a marvelous synthesis of pertinent scientific literature from the late nineteenth century to the modern day, by someone who has an intimate firsthand knowledge of what it is like to have worked in this field. * - Neerja Sankaran, ISIS (A Journal of the History of Science Society) *


An enjoyable read and I would thoroughly recommend it to anyone who wants to learn about the stories that lie behind the modern textbook understanding of the antibody molecule and its therapeutic applications. Mike Clark, Reader in Therapeutic and Molecular Immunology (Retired), University of Cambridge; British Journal of Cardiology, 22 (25), 2015


The Antibody Molecule is a marvelous synthesis of pertinent scientific literature from the late nineteenth century to the modern day, by someone who has an intimate firsthand knowledge of what it is like to have worked in this field. - Neerja Sankaran, ISIS (A Journal of the History of Science Society) An enjoyable read and I would thoroughly recommend it to anyone who wants to learn about the stories that lie behind the modern textbook understanding of the antibody molecule and its therapeutic applications. Mike Clark, Reader in Therapeutic and Molecular Immunology (Retired), University of Cambridge; British Journal of Cardiology, 22 (25), 2015


Author Information

Anthony Rees is currently Principle at Rees Consulting AB, Uppsala, Sweden. He was lecturer in Molecular Biophysics and Student of Christ Church from 1980 to 1990 at the University of Oxford. From 1990-1997 he was Professor and Head of the School of Biology and Biochemistry, University of Bath where he is an Emeritus Professor and holds an Honorary Doctor of Science. In 1989 he was a scientific cofounder with Graham Richards of Oxford Molecular, which became one of the earliest UK biotechnology companies to be listed on the London Stock Exchange. He has been visiting Professor at the Universities of Montpellier and Lund, scientific director of the French company Synt:em, CEO of the Swedish company MIP Technologies and Chairman of the Board of the antibody technology company, F-star. He is a member of the American Association for the History of Science and has published more than 120 scientific papers, a number of books and is an inventor on more than 30 patents.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

Aorrng

Shopping Cart
Your cart is empty
Shopping cart
Mailing List